Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-1)

April 7, 2017 updated by: Bausch Health Americas, Inc.

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-1

The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16 and week 24. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
478

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Hasselt, Belgium, 3500
        • Research Site
      • Leuven, Belgium, 3000
        • Research Site
  • Bulgaria
      • Plovdiv, Bulgaria, 4003
        • Research Site
      • Plovdiv, Bulgaria, 4002
        • Research Site
      • Sofia, Bulgaria, 1612
        • Research Site
      • Sofia, Bulgaria, 1709
        • Research Site
      • Varna, Bulgaria, 9010
        • Research Site
  • Canada
      • Quebec, Canada, G1V 3M7
        • Research Site
    • Alberta
      • Calgary, Alberta, Canada, T2G 1B1
        • Research Site
      • Calgary, Alberta, Canada, T3A 2N1
        • Research Site
    • Ontario
      • Toronto, Ontario, Canada, M5T 2S8
        • Research Site
      • Waterloo, Ontario, Canada, N2J 1C4
        • Research Site
    • Quebec
      • Trois-Rivieres, Quebec, Canada, G8Z 1Y2
        • Research Site
  • Czech Republic
      • Brno, Czech Republic, 611 41
        • Research Site
      • Brno, Czech Republic, 638 00
        • Research Site
      • Ceske Budejovice, Czech Republic, 370 01
        • Research Site
      • Ostrava-Trebovice, Czech Republic, 722 00
        • Research Site
      • Pardubice, Czech Republic, 530 02
        • Research Site
      • Praha 2, Czech Republic, 128 50
        • Research Site
      • Uherske Hradiste, Czech Republic, 686 01
        • Research Site
  • Estonia
      • Pärnu, Estonia, 80010
        • Research Site
      • Tallinn, Estonia, 10117
        • Research Site
  • France
      • Cahors Cedex, France, 46005
        • Research Site
      • Orleans cedex 2, France, 45067
        • Research Site
      • Rennes cedex 2, France, 35203
        • Research Site
      • Saint-Etienne Cedex 2, France, 42055
        • Research Site
      • Toulouse Cedex 9, France, 31059
        • Research Site
      • Tours Cedex 1, France, 37044
        • Research Site
  • Greece
      • Athens, Greece, 11527
        • Research Site
      • Athens, Greece, 16673
        • Research Site
      • Athens, Greece, 12462
        • Research Site
      • Athens, Greece, 16121
        • Research Site
      • Heraklion, Greece, 71110
        • Research Site
      • Thessaloniki, Greece, 56429
        • Research Site
  • Hungary
      • Budapest, Hungary, 1062
        • Research Site
      • Budapest, Hungary, 1036
        • Research Site
      • Debrecen, Hungary, 4032
        • Research Site
      • Esztergom, Hungary, 2500
        • Research Site
      • Nyiregyhaza, Hungary, 4400
        • Research Site
      • Szekesfehervar, Hungary, 8000
        • Research Site
      • Szolnok, Hungary, 5000
        • Research Site
  • Italy
      • Firenze, Italy, 50134
        • Research Site
      • Milano, Italy, 20122
        • Research Site
      • Pavia, Italy, 27100
        • Research Site
      • Roma, Italy, 00152
        • Research Site
      • Roma (RM), Italy, 00133
        • Research Site
      • Rome, Italy, 00144
        • Research Site
      • Verona, Italy, 37126
        • Research Site
  • Mexico
      • Chihuahua, Mexico, 31000
        • Research Site
      • Distrito Federal, Mexico, 03100
        • Research Site
    • Baja California Norte
      • Mexicali, Baja California Norte, Mexico, 21100
        • Research Site
    • Guanajuato
      • Leon, Guanajuato, Mexico, 37520
        • Research Site
    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44650
        • Research Site
      • Guadalajara, Jalisco, Mexico, 44160
        • Research Site
      • Guadalajara, Jalisco, Mexico, 44620
        • Research Site
    • Sonora
      • Ciudad Obregon, Sonora, Mexico, 85000
        • Research Site
    • Yucatán
      • Merida, Yucatán, Mexico, 97133
        • Research Site
  • Poland
      • Gdansk, Poland, 80-952
        • Research Site
      • Gdynia, Poland, 81-384
        • Research Site
      • Katowice, Poland, 40-040
        • Research Site
      • Lodz, Poland, 90-436
        • Research Site
      • Lodz, Poland, 90-242
        • Research Site
      • Lublin, Poland, 20-607
        • Research Site
      • Poznan, Poland, 61-113
        • Research Site
      • Stalowa Wola, Poland, 37-450
        • Research Site
      • Swidnik, Poland, 21-040
        • Research Site
      • Warszawa, Poland, 01-192
        • Research Site
      • Warszawa, Poland, 04-141
        • Research Site
      • Warszawa, Poland, 02-118
        • Research Site
      • Warszawa, Poland, 02-653
        • Research Site
      • Wroclaw, Poland, 50-088
        • Research Site
      • Wroclaw, Poland, 50-368
        • Research Site
      • Wroclaw, Poland, 51-318
        • Research Site
  • Russian Federation
      • Ekaterinburg, Russian Federation, 620102
        • Research Site
      • Moscow, Russian Federation, 115522
        • Research Site
      • Moscow, Russian Federation, 127473
        • Research Site
      • Nizhniy Novgorod, Russian Federation, 603126
        • Research Site
      • Nizhny Novgorod, Russian Federation, 603005
        • Research Site
      • Novosibirsk, Russian Federation, 630099
        • Research Site
      • Saint-Petersburg, Russian Federation, 190068
        • Research Site
      • Saratov, Russian Federation, 410012
        • Research Site
      • Yaroslavl, Russian Federation, 150062
        • Research Site
  • Slovakia
      • Banska Bystrica, Slovakia, 974 05
        • Research Site
      • Lucenec, Slovakia, 984 01
        • Research Site
      • Rimavska Sobota, Slovakia, 979 01
        • Research Site
      • Zilina, Slovakia, 01001
        • Research Site
  • Spain
      • Madrid, Spain, 28031
        • Research Site
      • Madrid, Spain, 28007
        • Research Site
    • Andalucía
      • Cordoba, Andalucía, Spain, 14004
        • Research Site
      • Granada, Andalucía, Spain, 18014
        • Research Site
      • Sevilla, Andalucía, Spain, 41009
        • Research Site
    • Cataluña
      • Barcelona, Cataluña, Spain, 08036
        • Research Site
      • Barcelona, Cataluña, Spain, 08041
        • Research Site
      • Hospitalet de Llobregat, Cataluña, Spain, 08907
        • Research Site
      • Sabadell, Cataluña, Spain, 08208
        • Research Site
    • Comunidad Valenciana
      • La Vila-Joiosa, Comunidad Valenciana, Spain, 03570
        • Research Site
    • Extremadura
      • Merida, Extremadura, Spain, 06800
        • Research Site
    • Galicia
      • A Coruña, Galicia, Spain, 15006
        • Research Site
  • Switzerland
      • Basel, Switzerland, 4031
        • Research Site
      • Geneva 14, Switzerland, 1211
        • Research Site
      • Lausanne, Switzerland, 1011
        • Research Site
      • Zurich, Switzerland, 8091
        • Research Site
  • United Kingdom
      • Birmingham, United Kingdom, B15 2TH
        • Research Site
      • Glasgow, United Kingdom, G31 2ER
        • Research Site
      • Hull, United Kingdom, HU3 2JZ
        • Research Site
      • Leeds, United Kingdom, LS7 4SA
        • Research Site
      • London, United Kingdom, SE1 9RT
        • Research Site
      • London, United Kingdom, E11 1NR
        • Research Site
      • Manchester, United Kingdom, M13 9WL
        • Research Site
  • United States
    • Alabama
      • Huntsville, Alabama, United States, 35801
        • Research Site
      • Tuscaloosa, Alabama, United States, 35406
        • Research Site
    • Arizona
      • Peoria, Arizona, United States, 85381
        • Research Site
      • Scottsdale, Arizona, United States, 85258
        • Research Site
    • California
      • Los Angeles, California, United States, 90095
        • Research Site
      • Mather, California, United States, 95655
        • Research Site
      • Murrieta, California, United States, 92563
        • Research Site
      • Palm Desert, California, United States, 92260
        • Research Site
      • Tustin, California, United States, 92780
        • Research Site
      • Upland, California, United States, 91786
        • Research Site
    • Florida
      • Jupiter, Florida, United States, 33458
        • Research Site
      • Tamarac, Florida, United States, 33321
        • Research Site
      • Tampa, Florida, United States, 33613
        • Research Site
    • Georgia
      • Gainesville, Georgia, United States, 30501
        • Research Site
    • Idaho
      • Meridian, Idaho, United States, 83642
        • Research Site
    • Illinois
      • Springfield, Illinois, United States, 62703
        • Research Site
    • Kentucky
      • Bowling Green, Kentucky, United States, 42101
        • Research Site
      • Somerset, Kentucky, United States, 42503
        • Research Site
    • Maryland
      • Frederick, Maryland, United States, 21702
        • Research Site
      • Wheaton, Maryland, United States, 20902
        • Research Site
    • Massachusetts
      • Worcester, Massachusetts, United States, 01605
        • Research Site
    • Michigan
      • Lansing, Michigan, United States, 48910
        • Research Site
    • Minnesota
      • Eagan, Minnesota, United States, 55121
        • Research Site
    • Nebraska
      • Omaha, Nebraska, United States, 68114
        • Research Site
    • New Jersey
      • Clifton, New Jersey, United States, 07012
        • Research Site
    • New York
      • Great Neck, New York, United States, 11021
        • Research Site
      • Lake Success, New York, United States, 11042
        • Research Site
      • New York, New York, United States, 10016
        • Research Site
      • Plainview, New York, United States, 11803
        • Research Site
    • North Carolina
      • Asheville, North Carolina, United States, 28803
        • Research Site
    • Oregon
      • Bend, Oregon, United States, 97701
        • Research Site
      • Portland, Oregon, United States, 97239
        • Research Site
    • Pennsylvania
      • Duncansville, Pennsylvania, United States, 16635
        • Research Site
    • South Carolina
      • Charleston, South Carolina, United States, 29406
        • Research Site
    • Tennessee
      • Hixson, Tennessee, United States, 37343
        • Research Site
    • Texas
      • Austin, Texas, United States, 78731
        • Research Site
      • Houston, Texas, United States, 77074
        • Research Site
      • San Antonio, Texas, United States, 78232
        • Research Site
    • Virginia
      • Danville, Virginia, United States, 24541
        • Research Site
    • Washington
      • Seattle, Washington, United States, 98104
        • Research Site
    • West Virginia
      • Beckley, West Virginia, United States, 25801
        • Research Site
      • Bridgeport, West Virginia, United States, 26330
        • Research Site
    • Wisconsin
      • Glendale, Wisconsin, United States, 53217
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subject has a diagnosis of psoriatic arthritis (by the Classification of Psoriatic Arthritis criteria (CASPAR), with ≥ 3 tender and ≥ 3 swollen joints (excluding the distal interphalangeal joints)).
  • Subjects must have at least 1 psoriatic skin lesion as well as either ≥ 1 erosion on a centrally read radiograph or an elevated CRP.

Exclusion Criteria:

  • Subject has known history of active tuberculosis.
  • Subject has a planned surgical intervention between baseline and the week 52 evaluation.
  • Subject has an active infection or history of infections.
  • Subject has any systemic disease (eg, renal failure, heart failure, hypertension, liver disease, diabetes, anemia) considered by the Investigator to be clinically significant and uncontrolled.
  • Subject has any concurrent medical condition or electrocardiogram (ECG) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject.
  • Subject has severe depression measured by Personal Health Questionnaire Depression Scale (PHQ-8) or suicidal ideation/behavior as measured by and Columbia Suicide Severity Rating Scale (e-CSSRS)
  • Subject has a history or evidence of psychiatric disorder or substance abuse considered by the Investigator to pose a risk to subject safety

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
EXPERIMENTAL: 210 mg brodalumab
Administered via subcutaneous injections
Drug: 210 mg brodalumab
210 mg brodalumab administered via subcutaneous injection
Other Names:
  • AMG 827
EXPERIMENTAL: 140 mg brodalumab
Administered via subcutaneous injection
Drug: 140 mg brodalumab
140 mg brodalumab administered via subcutaneous injection
Other Names:
  • AMG 827
PLACEBO_COMPARATOR: Placebo
Administered via subcutaneous injection until week 24.
Drug: Placebo
Placebo administered via subcutaneous injection until week 24.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
American College of Rheumatology (ACR) 20 Response
Time Frame: 16 weeks
An ACR20 response is defined as at least 20% improvement of tender and swollen joint counts combined with at least 20% improvement in at least 3 of the following 5 parameters: Patients Global Assessment, PtGA of disease activity, patient's assessment of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), and either Erythrocycte sedimentation rate (ESR) or C-Reactive protein (CRP) (ACR components).
16 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Psoriasis Area and Severity Index (PASI)75
Time Frame: 16 Weeks
PASI75 indicates that the subject has had a response of a 75% reduction on the severity of the psoriasis area based of off effected area size, erythema, scaling, and itching.
16 Weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bausch Health Americas, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2014

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 1, 2015

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 1, 2015

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 6, 2014

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 6, 2014

First Posted (ESTIMATE)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 8, 2014

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 19, 2017

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 7, 2017

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 20090406
  • 2013-003554-25 (EUDRACT_NUMBER)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings